Sampling Human
Sampling Human builds production systems for generating cellular-resolution data from clinical samples, serving diagnostic, health, and research organizations with a proprietary sequencing platform, cloud service, and sample collection kits.
- Company typePrivate
- Founded2022
- HeadquartersBerkeley, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Sampling Human does
Sampling Human is a private biotechnology company founded in 2022 that builds production systems for generating cellular-resolution data from clinical samples. Headquartered in Berkeley, California with a technical operations office in Pilsen, Czech Republic, the company operates with a headcount between 11 and 50 employees and serves diagnostic, health, and research organizations. Its positioning is built on converting variable clinical inputs and application-specific biology into standardized, structured cellular data at production scale, with three named vertical focuses: longevity (N-of-1 health intelligence), prenatal (non-invasive fetal genetics and placental function), and oncology (mechanistic disease monitoring).
The platform architecture is composed of five integrated components: proprietary Encoding Chemistry (multidimensional barcoding that overcomes existing barcoding limits and scales per sample), Selective Singulation (focused sequencing on relevant cells and signals), AI Decoding Models (a foundation model that maps barcode space into sample-level representations and shifts assay complexity to computation), Physical Tokenization (automated quality-controlled annotations across novel patient-specific cellular states), and Production Layer Integration (an end-to-end workflow designed for automated molecular lab infrastructure). Commercially, the company delivers the Sequencing Platform and Cloud Service under subscription, supported by physical SamplingOne™ Kits for sample collection and Technical Services for sample processing, with quote-based pricing, 30-day quotation validity, and 30-day payment terms.
The company has raised approximately $2 million in seed funding (April 2022) led by i&i Biotech Fund, with participation from Longevitytech.fund and Formic Ventures. It is co-founded by Daniel Georgiev (CEO), Hynek Kasl (Head of Engineering), and Martin Cienciala (Head of Innovation). The go-to-market is enterprise-focused through direct outreach to diagnostic, health, and research organizations, supplemented by digital channels (LinkedIn, Twitter/X, email newsletter, website content). No named customers, revenue figures, follow-on financing events, or commercialization milestones have been disclosed in the available data.
Sampling Human firmographics
Firmographics- Name
- Sampling Human
- Legal name
- Sampling Human, Inc.
- Website
- https://samplinghuman.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Sampling Human builds production systems for generating cellular-resolution data from clinical samples, serving diagnostic, health, and research organizations with a proprietary sequencing platform, cloud service, and sample collection kits.
- Ownership category
- akta.pro rank
Sampling Human industry classification
Industry- Product category
- Genomics Sequencing Platform
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
- akta.pro secondary industries
- Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Sampling Human is headquartered
LocationHeadquarters
- HQ city
- Berkeley
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Sampling Human business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Platform Subscription: Customers subscribe to access the Sequencing Platform and Cloud Service. Access is granted for internal business purposes during the Services Term with non-exclusive, non-transferable rights.
- SamplingOne™ Kit Sales: Sale of physical kit components for sample collection and processing. Kits are shipped to customers with warranty coverage until the expiration date on the package.
- Technical Services: Technical or professional services performed by Sampling Human as described in applicable Orders, including processing Customer Samples.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Custom quotation-based pricing |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Sampling Human product offering
Product offeringCore offering
Sampling Human builds production systems for generating cellular-resolution data from clinical samples, combining a Sequencing Platform, a Cloud Service, and a physical SamplingOne™ Kit. The platform applies proprietary multidimensional encoding chemistry and AI decoding models to convert clinical samples into standardized, structured cellular data for diagnostics, health products, and AI models. Revenue is generated through platform subscriptions, kit sales, and technical services via direct enterprise sales.
Product overview
Sampling Human offers a unified platform for generating cellular-resolution data from clinical samples. The core offering consists of the Sequencing Platform (software and analysis system), Cloud Service (for data upload and management), and SamplingOne™ Kit (physical sample collection component), supported by Technical Services. The platform is built on proprietary Encoding Chemistry and Decoding Models that work together to transform complex clinical samples into standardized, structured cellular data at production scale for diagnostics, health products, and AI models.
Differentiator
Problem solved
Functional benefit
Products and services
- Sequencing Platform Sampling Human's platform application including all related software, hardware, products, processes, algorithms, user interfaces, know-how, techniques, designs, and other technical material for generating cellular-resolution data from clinical samples. Made available to customers pursuant to an Order.
- Cloud Service The cloud-based platform through which users can upload their sequences for analysis by Sampling Human, including the content of the platform, algorithms, and machine learning capabilities. Accessed via the hosted website.
- SamplingOne™ Kit A physical kit for sample collection designed for stable sample collection and integration with the Sequencing Platform for automated molecular lab infrastructure. Kits are shipped to customers with warranty coverage until the expiration date on the package.
- Technical Services Technical or professional services performed by Sampling Human as described in an applicable Order, including processing Customer Samples and generating Results.
Quantifiable outcome
- Platform generates cellular-resolution data at clinical scale
Companies that use Sampling Human
Customer profileSegments3 records
Ideal customer profiles3 records
Sampling Human technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Sampling Human partnerships and signals
Strategic signalScale indicators1 record
Recent moves6 records
Expansion highlights5 records
Sampling Human competitors and assessment
Company assessmentDirect peers
- 10x Genomics: 10x Genomics is the dominant single-cell sequencing platform provider (Chromium, Visium, Xenium). It is the closest direct competitor to Sampling Human's cellular-resolution sequencing platform, with overlapping applications in oncology, immunology, and translational research.
- Mission Bio: Mission Bio provides single-cell multi-omics platforms (Tapestri) focused on oncology and clinical applications such as measurable residual disease. Like Sampling Human, it targets clinical and translational research customers with single-cell resolution for patient-level biology.
- Parse Biosciences: Parse Biosciences offers scalable single-cell sequencing solutions (Evercode) used in research and translational settings. It competes with Sampling Human in providing high-throughput, lower-touch single-cell workflows for clinical and research customers.
- Fluent Biosciences: Fluent Biosciences develops single-cell sequencing technologies with a focus on simplified, scalable workflows. Its product positioning around cost-effective, automation-friendly single-cell prep directly overlaps with Sampling Human's production-scale platform.
- Akoya Biosciences: Akoya Biosciences provides spatial biology and single-cell analysis platforms (CODEX, Phenoptics) used in immuno-oncology and translational research. It overlaps with Sampling Human's cellular-resolution value proposition, particularly for oncology and immune profiling applications.
Broad incumbents
- Becton, Dickinson and Company (BD) — BD Biosciences: BD's Rhapsody single-cell platform and broader life-sciences instrumentation portfolio make it a broad incumbent offering overlapping cellular-resolution capabilities. BD competes with Sampling Human across research and clinical research customers and benefits from an entrenched installed base.
- Illumina: Illumina is the dominant sequencing platform provider (NovaSeq, NextSeq) whose instruments underlie most single-cell workflows, including Sampling Human's. While not a direct single-cell competitor, Illumina's technology and reagent ecosystem set the performance and cost benchmark for any new entrant.
- Bio-Rad Laboratories: Bio-Rad offers ddSEQ single-cell sequencing solutions and a broad life-science research portfolio. As a broad incumbent, it competes with Sampling Human across research customers and benefits from established distribution and reagent pull-through.
Emerging players
- Element Biosciences: Element Biosciences is an emerging sequencing platform company (AVITI) competing with incumbents on cost and flexibility. While not a single-cell pure play, its lower-cost benchtop sequencing instrument could be an enabling or competing technology for Sampling Human-style workflows.
- Singular Genomics: Singular Genomics develops benchtop sequencers (G4) aimed at flexible, lower-cost sequencing for research and clinical applications. It is an emerging infrastructure competitor whose platform choices affect how customers approach single-cell and cellular-resolution workflows.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Sampling Human social profiles
Digital presenceSampling Human financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sampling Human leadership team
Management profileNumber of profiles
Profiles6 records
Sampling Human funding detail
Funding detailFunding overview
Funding rounds1 record
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sampling Human M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sampling Human
What does Sampling Human do?
Sampling Human builds production systems for generating cellular-resolution data from clinical samples, combining a Sequencing Platform, a Cloud Service, and a physical SamplingOne™ Kit. The platform applies proprietary multidimensional encoding chemistry and AI decoding models to convert clinical samples into standardized, structured cellular data for diagnostics, health products, and AI models. Revenue is generated through platform subscriptions, kit sales, and technical services via direct enterprise sales.
Is Sampling Human a public or private company?
Sampling Human is a private company. It is classified as venture growth investor backed and is currently operating.
When was Sampling Human founded?
Sampling Human was founded in 2022. It employs 11 to 50 people.
Where is Sampling Human based?
Sampling Human is headquartered in Berkeley, United States, in the North America region.
How does Sampling Human make money?
Three revenue lines are on record. Platform Subscription is the primary driver. The others are samplingOne™ Kit Sales and technical Services.
Who are Sampling Human's main competitors?
Direct peers on record are 10x Genomics, Mission Bio, Parse Biosciences, Fluent Biosciences and Akoya Biosciences. Broad incumbents are Becton, Dickinson and Company (BD) — BD Biosciences, Illumina and Bio-Rad Laboratories. Emerging players are Element Biosciences and Singular Genomics.
Does Sampling Human have an API?
No public API is recorded for Sampling Human.
What industry is Sampling Human in?
Sampling Human's product category is Genomics Sequencing Platform. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAHAAAN, Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics). Its NAICS code is 325413 and its SIC code is 2835.